Navigation Links
Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
Date:9/17/2007

of the mechanisms of resistance in malignant gliomas is AGT. We are hoping that we can deplete the level of AGT with Temodar(R) and that the combination of agents will improve anti-tumor responses and outcomes. To date there is no standard therapy for malignant gliomas that recur; if we can increase progression- free and overall survival with this combination, we will be able to help patients."

Ann Cahill, Vice President, Clinical Development, said, "Despite decades of research, there has been little progress in the treatment of malignant gliomas which recur after primary therapy. We are pleased to support Dr. Raizer's study of Cloretazine(R) (VNP40101M) in this patient population."

Cloretazine(R) (VNP40101M) has previously been evaluated as a single agent in a Phase II clinical trial in patients with recurrent glioblastoma multiforme (Badruddoja MA et al, 2007 Neuro-Oncology; 9: 70-74). In addition, a Phase I trial of Cloretazine(R) (VNP40101M) as a single agent in pediatric brain tumors was recently completed. Data from this trial were presented at the American Society of Clinical Oncology Annual Meeting in June 2007.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) in small cell lung cancer and adult brain tumors are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company is seek
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Haemonetics Corporation (NYSE: HAE ) announced today that ... will present at The Deutsche Bank 38 th Annual ... on May 29, 2013 at 1:30pm Eastern time.  ... public may access Mr. Lindop,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
(Date:5/23/2013)... 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... company, today scheduled a conference call to discuss its ... 2013, ended April 30, 2013. The call will be ... The Company will report financial results for the second ... on Thursday, May 30, 2013. (Logo: ...
(Date:5/23/2013)... Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly ... property developed and owned by Hadassah University Hospital, ... center, today announced that its portfolio company, Cell ... Israeli Ministry of Industry and Commerce, Office of ... and advance clinical trials. Cell Cure,s development budget ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
(Date:5/25/2013)... Plains, NJ (PRWEB) May 25, 2013 ... iPhone. The universal app version of Word Hunt ... app versions of Concentration, Edge Match, Flash 2, Sudoku and ... , The brain games’ gameplay and revolutionary lifetime brain fitness ... 4 inch displays. , “100 years of brain fitness measurement ...
(Date:5/25/2013)... Los Angeles, CA (PRWEB) May 25, 2013 ... will grow at an average annual rate of 28.7% ... growth of 17.9% in 2013. From 2002 and 2008, no ... analyst Kevin Culbert, causing relatively modest growth during that period. ... (FDA) has approved six new products. This factor contributed to ...
(Date:5/25/2013)... Texas (PRWEB) May 25, 2013 ... stressful than finals week. Increasingly, they are turning ... stay awake and study. For more on this, ... a drug treatment facility, warns that students who ... finals” are at risk for developing a physical ...
(Date:5/25/2013)... 2013 Ayurveda is the traditional ... or wisdom of life". While a medical science, its scope ... of consciousness. Its fundamental philosophy is that disease is the ... It believes that in order to re-establish optimal health, we ... then adopt a life style which brings us back into ...
(Date:5/25/2013)... May 25, 2013 The current residents of ... parents, and the B2B staff all came together Saturday, May ... an array of Indian Cuisine, the residents got up to ... helping them on their road to recovery, and giving them ... and Alcohol center in 2010 after realizing the need for ...
Breaking Medicine News(10 mins):Health News:Acuity Games Apps Come to the iPhone 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2
... more sensitive to early signs of Alzheimer,s dementia than ... School of Medicine in St. Louis. Doctors often ... testing them with a variety of cognitive tasks, such ... of objects. Washington University researchers developed a different approach. ...
... By Randy Dotinga HealthDay Reporter , MONDAY, Sept. ... the devastation suffered by men when their wives or girlfriends ... were almost 40 percent more likely than other men to ... risk of hospitalization among the men was very small, and ...
... Inc. is presenting new data in five posters and ... the company,s radioprotectant Ex-RAD at the 56th Annual Meeting ... Maui, Hawaii. In vivo studies show that Ex-RAD, ... versus placebo-treated groups in mice exposed to lethal whole ...
... best practice and endorsement of evidence-based medicine, the American ... and released a clinical practice guideline, which found a ... a way to treat fractures in the spine. ... to ensure that patients receive high quality care. ...
... and military efforts continuing in Afghanistan, UCLA has helped ... forces medical personnel in critical combat casualty care. The ... program,s developers say, but civilian care as well. ... the field during Operation Iraqi Freedom and Operation Enduring ...
... first studies to focus exclusively on the outcomes ... http://www.mayoclinic.org/prostate-cancer/ ) researchers have found that surgery provides ... and Fox Chase Cancer Center ( http://www.fccc.edu/ ) ... aggressive forms of prostate cancer who had radical ...
Cached Medicine News:Health News:Friends, family detect early Alzheimer's signs better than traditional tests 2Health News:Friends, family detect early Alzheimer's signs better than traditional tests 3Health News:Male Partners of Breast Cancer Patients May Suffer Depression 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 3Health News:New guideline finds no evidence for a popular back procedure 2Health News:New guideline finds no evidence for a popular back procedure 3Health News:UCLA develops combat casualty care educational program for US armed forces 2Health News:UCLA develops combat casualty care educational program for US armed forces 3Health News:Surgery found effective for patients with aggressive prostate cancer 2
... for a complete line of diagnostic coronary ... with the quality, reliability and precise performance ... in catheter technology. All of our coronary ... to help minimize the frustration and excess ...
The Polaris-DX steerable diagnostic catheter is designed for comfort and ergonomic handling during mapping procedures....
... of the PARAHISIAN catheter, combines an octapolar ... permits the use of only one catheter ... His bundle electrograms. The "two catheters in ... a single venipuncture. The disadvantages of using ...
... HIS diagnostic catheters provide the ... curve that allows for placement ... bundle. In addition, the soft ... the risk of perforation while ...
Medicine Products: